Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.

Number of participants with severe side effects from study treatment during the DLT evaluation period (6 weels)

The best response recorded from the start of the study treatment until the end of treatment according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1, taking into account any requirement for confirmation of response.

Complete response (CR) is defined as disappearance of all target and non-target lesions.

Partial response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, no progression of non-target lesions, and no new lesions.

Progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, or unequivocal progression of non-target lesions, or appearance of new lesions.

Stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as progression.

Not evaluable (NE) is where the response cannot be determined.

All participants who received at least one dose of study drug, had baseline measurable or non-measurable disease, and had at least one post-baseline radiographic tumor assessment or discontinued treatment due to clinical progressive disease or death.

The percentage of participants who achieve a complete response (CR or partial response (PR) to treatment with vobramitamab duocarmazine

PFS is calculated from the first dose date until the date of first documented PD using RECIST v1.1, or death from any cause, whichever occurs first.

Progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, or unequivocal progression of non-target lesions, or appearance of new lesions. Median PFS and 95% CI is estimated using the Kaplan-Meier method.

Median DoR assessed as the time from the date of initial objective response to the date of first documented PD, per RECIST v1.1, or the date of death from any cause, whichever occurs first.

Median DoR and 95% CI is estimated using the Kaplan-Meier method.

Participants who experienced a complete or partial response to study treatment.

Median OS assessed as the time from the first dose date to the date of death from any cause, using the Kaplan-Meier method for estimating median and confidence interval. .

Percent of prostate cancer patients with at least 50% reduction in prostate-specific antigen (PSA) with confirmation at least 3 weeks later

For prostate cancer patients, the greatest change from baseline in PSA.

Area under the plasma concentration versus time curve of vobramitamab duocarmazine

All participants who received at least one dose of study treatment, date and time of dose administration and relative PK sample collection are known and have sufficient concentration data to derive the PK parameter. One participant assigned to Cohort 4 (3.0 mg/kg dose) was actually treated at the Cohort 3 dose of 2.0 mg/kg and is therefore included in Cohort 3 for the purposes of this analysis.

Area under the plasma concentration versus time curve of duocarmycin (unconjugated payload) in the bloodstream

All participants who received at least one dose of study treatment, date and time of dose administration and relative PK sample collection are known and have sufficient concentration data to derive the PK parameter. One participant assigned to Cohort 4 (3.0 mg/kg dose) was actually treated at the Cohort 3 dose of 2.0 mg/kg and is therefore included in Cohort 3 for the purposes of this analysis.

Maximum Plasma Concentration of vobramitamab duocarmazine ADC in the bloodstream

All participants who received at least one dose of study treatment, date and time of dose administration and relative PK sample collection are known and have sufficient concentration data to derive the PK parameter. One participant assigned to Cohort 4 (3.0 mg/kg dose) was actually treated at the Cohort 3 dose of 2.0 mg/kg and is therefore included in Cohort 3 for the purposes of this analysis

Maximum Plasma Concentration of vobramitamab duocarmazine ADC in the bloodstream

All participants who received at least one dose of study treatment, date and time of dose administration and relative PK sample collection are known and have sufficient concentration data to derive the PK parameter. One participant assigned to Cohort 4 (3.0 mg/kg dose) was actually treated at the Cohort 3 dose of 2.0 mg/kg and is therefore included in Cohort 3 for the purposes of this analysis

Average trough plasma concentration of vobramitamab duocarmazine ADC in the bloodstream.

All participants who received at least one dose of study treatment, date and time of dose administration and relative PK sample collection are known and have sufficient concentration data to derive the PK parameter. One participant assigned to Cohort 4 (3.0 mg/kg dose) was actually treated at the Cohort 3 dose of 2.0 mg/kg and is therefore included in Cohort 3 for the purposes of this analysis.

Average trough plasma concentration of duocarmycin unconjugated payload in the bloodstream.

All participants who received at least one dose of study treatment, date and time of dose administration and relative PK sample collection are known and have sufficient concentration data to derive the PK parameter. One participant assigned to Cohort 4 (3.0 mg/kg dose) was actually treated at the Cohort 3 dose of 2.0 mg/kg and is therefore included in Cohort 3 for the purposes of this analysis.

Shifts in MGC018 anti-drug antibodies after treatment with vobramitamab duocarmazine

All participants who received at least one dose of study treatment and have at least one ADA sample sufficient for analysis. There were 3 missing samples.